All In Biotech

NDA 209360 · La Jolla Pharma

Giapreza

Angiotensin Ii Acetate · Intravenous · Vasoconstrictor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Dec 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 21, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

273

53 Phase 3, 35 recruiting

FAERS reports

300

273 serious, 95 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 22, 2026.

1. INDICATIONS AND USAGE GIAPREZA increases blood pressure in adults with septic or other distributive shock [see Clinical Studies (14)] . GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. ( 1 )

Mechanism: Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca 2+ /calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 21, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
  • GIAPREZA · ANGIOTENSIN II ACETATE EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • GIAPREZA · ANGIOTENSIN II ACETATE EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • GIAPREZA · ANGIOTENSIN II ACETATE EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Angiotensin Ii" as an intervention, any sponsor and status, largest first.

All 273 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective72
  • off label use31
  • death26
  • acute kidney injury25
  • toxicity to various agents19
  • distributive shock17
  • peripheral ischaemia17
  • hypotension16
  • overdose16
  • intestinal ischaemia15
  • cardiac arrest13
  • cardiogenic shock12

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20072
20081
20093
20103
20117
201213
20131
20144
20152
20163
20173
201812
201929
202018
202130
202238
202343
202419
202534
202634

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,219 on PubMed

Sponsor: La Jolla Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.